Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study

This multicenter, open‐label phase 1/2 study evaluated single‐agent carfilzomib in 50 heavily pretreated Japanese patients with relapsed/refractory multiple myeloma (median of five prior treatments). In phase 1, patients were dosed at three levels: 15, 20, or 20/27 mg/m(2). Maximum tolerated dosage...

詳細記述

保存先:
書誌詳細
出版年:Cancer Sci
主要な著者: Iida, Shinsuke, Watanabe, Takashi, Matsumoto, Morio, Suzuki, Kenshi, Sunami, Kazutaka, Ishida, Tadao, Ando, Kiyoshi, Chou, Takaaki, Ozaki, Shuji, Taniwaki, Masafumi, Uike, Naokuni, Shibayama, Hirohiko, Hatake, Kiyohiko, Izutsu, Koji, Ishikawa, Takayuki, Shumiya, Yoshihisa, Tobinai, Kensei
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2019
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726678/
https://ncbi.nlm.nih.gov/pubmed/31336012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14139
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料